Drug Profile
Pegcrisantaspase - Jazz Pharmaceuticals Inc
Alternative Names: Asparec; JZP-416; mPEG-R-crisantaspase; PEG-crisantaspase; Pegylated-crisantaspase; PEGylated-Erwinia-chrysanthemi-L-asparaginase; Polyethylene-glycol-Erwinia-chrisanthemi-L-asparaginaseLatest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Alize Pharma II SAS
- Developer EUSA Pharma; Jazz Pharmaceuticals Inc
- Class Amidohydrolases; Antineoplastics; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Amidohydrolase stimulants; Aspartate-ammonia ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I Acute myeloid leukaemia
- No development reported Haematological malignancies
Most Recent Events
- 09 Dec 2023 Final efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 28 Aug 2020 M.D. Anderson Cancer Center and National Cancer Institute plans a phase I trial for Leukemia (Second line therapy or greater) in USA (NCT04526795)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in France (IV, Infusion)